How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,896 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis. (Abstract)

Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis. Evidence from adult psoriasis studies implicates an imbalance between regulatory and effector T cells, particularly TH-17-producing T cells, in the pathogenesis of psoriasis. Little is known about the immunopathology of psoriasis in children.We sought to functionally characterize the inflammatory cell profiles of psoriatic plaques from pediatric patients and compare them with healthy, age (...) -matched controls and adult psoriasis patients.Skin samples from pediatric psoriasis patients and healthy controls were analyzed by multiparameter flow cytometry to determine the dominant immune cell subsets present and cytokines produced.Lesional tissue from pediatric psoriasis patients had significantly increased interleukin (IL) 22 derived from CD4+ and CD8+ cells compared with the tissues from healthy pediatric controls and adult psoriasis patients. Tissue from pediatric psoriasis patients had

2017 Journal of American Academy of Dermatology

182. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. (Abstract)

Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. The Australasian Psoriasis Collaboration has reviewed the evidence for managing moderate to severe psoriasis in those who are pregnant or are breast-feeding, or planning a family. The severity of the psoriasis, associated comorbidities and specific anti-psoriasis treatment, along with other exposures, can have a deleterious effect on pregnancy outcomes. Psoriasis itself increases the risk (...) of preterm and low birthweight babies, along with spontaneous and induced abortions, but no specific birth defects have been otherwise demonstrated. The baseline risk for a live born baby to have a major birth defect is 3%, and significant neuro-developmental problem is 5%. In Australia, pregnant women with psoriasis are more likely to be overweight or obese, depressed, or smoke in their first trimester, and are also less likely to take prenatal vitamins or supplements. Preconception counselling

2017 Australasian Journal of Dermatology

183. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. Full Text available with Trip Pro

Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. Tofacitinib is an oral Janus kinase inhibitor. Efficacy and safety of tofacitinib in patients with moderate-to-severe plaque psoriasis have been demonstrated.We sought to assess the efficacy of tofacitinib for the treatment of nail psoriasis over a period of 52 weeks.In 2 identical phase 3 studies (OPT Pivotal 1 and 2), patients (...) were randomized 2:2:1 to receive tofacitinib 5 mg, tofacitinib 10 mg, or placebo, twice daily. At week 16, placebo-treated patients were re-randomized to tofacitinib. This post hoc analysis of patients with existing nail psoriasis assessed the Nail Psoriasis Severity Index (NAPSI) score and proportions of patients achieving ≥50% reduction in NAPSI from baseline (NAPSI50), NAPSI75, or NAPSI100.Baseline mean NAPSI scores for patients treated with tofacitinib 5 mg (N = 487), tofacitinib 10 mg (N = 476

2017 Journal of the American Academy of Dermatology Controlled trial quality: uncertain

184. Evaluation of psoriasis severity and inflammatory responses under concomitant treatment with methotrexate plus micronutrients for psoriasis vulgaris: a randomized double blind trial. (Abstract)

Evaluation of psoriasis severity and inflammatory responses under concomitant treatment with methotrexate plus micronutrients for psoriasis vulgaris: a randomized double blind trial. We evaluated the effectiveness of concomitant treatment with methotrexate (MTX) plus micronutrients in comparison with monotherapy with MTX only in psoriasis patients. Plasma levels of interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) were also measured and their association with clinical severity (...) was evaluated.Thirty psoriasis patients 20 to 50 years old with a PASI score > 10 were divided randomly into two groups. Both groups were given oral methotrexate (0.2-0.3 mg/kg/week) for 12 weeks. In addition, Group B received one tablet of micronutrient supplement daily. Disease severity was calculated using the psoriasis area and severity index (PASI) score before and after 12 weeks. Levels of IL-1β and TNF-α were measured using enzyme-linked immunosorbent assay (ELISA).We found that 13 (86.6%) patients in Group

2017 Acta dermatovenerologica Alpina, Pannonica, et Adriatica Controlled trial quality: uncertain

185. Identification of PTPN22, ST6GAL1 and JAZF1 as Psoriasis Risk Genes Demonstrates Shared Pathogenesis between Psoriasis and Diabetes. (Abstract)

Identification of PTPN22, ST6GAL1 and JAZF1 as Psoriasis Risk Genes Demonstrates Shared Pathogenesis between Psoriasis and Diabetes. The biological connections between psoriasis and diabetes have been suggested by epidemiological, immunological and genetic studies. To identify additional shared susceptibility loci and investigate shared pathogenesis between these two diseases, we genotyped 89 reported diabetes susceptibility loci in 4456 psoriasis cases and 6027 controls of Chinese population (...) using the MassARRAY system from Sequenom. We discovered three significant associations at rs6679677 on 1p13.2 (P=6.15×10-5 , OR=5.07), rs16861329 on 3q27.3 (P=2.02×10-4 , OR=0.87) and rs849135 on 7p15.1 (P=6.59×10-9 , OR=1.78), which suggested PTPN22, ST6GAL1 and JAZF1 as novel susceptibility genes for psoriasis in Chinese population. Our findings implicated the involvement of T-cell receptor signalling pathway in the pathogenesis of psoriasis and further confirmed the shared genetic susceptibility

2017 Experimental Dermatology

186. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. Full Text available with Trip Pro

Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. Psoriasis is a common skin disease and moderate to severe psoriasis is associated with a dose-dependent risk for metabolic and cardiovascular morbidity. It has previously been speculated that women have less severe psoriasis, as men are overrepresented in psoriasis registers and consume more care.The objective of this study (...) was to investigate, for the first time, the sex differences in the severity of psoriasis using the gold standard of severity measurement, the Psoriasis Area and Severity Index (PASI), and the distinct elements of the PASI score.This was a cross-sectional study based on the national registry for systemic treatment of psoriasis in Sweden (PsoReg), with 5438 patients experiencing moderate to severe psoriasis. Differences in the PASI score and its elements at enrolment were tested by multivariable ordinal logistic

2017 American journal of clinical dermatology

187. Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. (Abstract)

Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. 28319281 2017 09 14 1468-3083 31 9 2017 Sep Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. e420-e421 10.1111/jdv.14234 Mugheddu C C Section of Dermatology, AOU of Cagliari - Department of Medical Science and Public Health, University of Cagliari, 09124

2017 Journal of the European Academy of Dermatology and Venereology

188. Rethinking costs of psoriasis: 10% of patients account for nearly 40% of healthcare expenditures among enrollees with psoriasis in a U.S. health plan. (Abstract)

Rethinking costs of psoriasis: 10% of patients account for nearly 40% of healthcare expenditures among enrollees with psoriasis in a U.S. health plan. To examine characteristics, healthcare utilization and costs among patients with psoriasis who have high medical costs.This is a retrospective study of patients with psoriasis with continuous enrollment from 1 January 2011 to 31 December 2013 in a large US health plan. Total paid 2012 healthcare costs excluding biologics (to identify costliest (...) not due to biologic costs) were used to create cohorts representing the top 10% (T10) and bottom 90% (B90) of expenditures. Demographics, comorbidities, prescriptions, all-cause and psoriasis-related healthcare utilization and costs were compared between cohorts. Logistic regression identified demographic and clinical characteristics associated with the 2012 T10 cohort status.18,653 patients (mean age 48 years; 49% female) were included. Patients in the T10 group accounted for 26% (2011), 39% (2012

2017 Journal of Dermatological Treatment

189. A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) shows country-specific features: Results from psoriasis patients in Spain. Full Text available with Trip Pro

A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) shows country-specific features: Results from psoriasis patients in Spain. The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey data were not analysed to account for cultural and healthcare system differences across European countries (EC).To utilize MAPP data to characterize psoriasis in Spanish patients, including severity assessment (...) and Dermatology Life Quality Index (DLQI).The MAPP survey was conducted between June and August 2012. This analysis included 1700 patients with self-reported psoriasis (without psoriatic arthritis) from France (n = 349), Germany (n = 311), Italy (n = 359), Spain (n = 354) and the United Kingdom (n = 327).Patients from Spain vs. other EC self-reported higher mean body mass index (26.9 vs. 25.6, P ≤ 0.001), lower prevalence of depression (6% vs. 12%, P = 0.002) and higher mean self-perceived psoriasis severity

2017 Journal of the European Academy of Dermatology and Venereology

190. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. (Abstract)

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. The emergence of new biological therapies showing high and sustained level of Psoriasis Area and Severity Index (PASI) 90 response has provided the possibility of both greater skin clearance and increased quality of life (QOL).To evaluate the association of greater response (...) . 56.7%; p < .001). IGA results were similar.These results show that PASI 90-100 is a relevant therapeutic goal in moderate to severe psoriasis compared to PASI 75-89 when considering patients' QOL.

2017 Journal of Dermatological Treatment Controlled trial quality: uncertain

191. Guselkumab for moderate to severe psoriasis

Guselkumab for moderate to severe psoriasis Guselkumab for moderate to severe psoriasis Guselkumab for moderate to severe psoriasis NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Guselkumab for moderate to severe psoriasis. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' objectives (...) Psoriasis is a skin condition that causes the skin to look red and flaky, with crusty patches of skin covered with silvery scales. These patches of skin are often sore and cause itching. Common areas for psoriasis patches to occur are the elbows, knees, scalp and lower back. The treatment of psoriasis is often successful, but does not completely cure the condition. Psoriasis usually comes and goes so there are times when a patient who has psoriasis may feel well, but other times when the condition

2016 Health Technology Assessment (HTA) Database.

192. Tofacitinib for chronic plaque psoriasis - second line

Tofacitinib for chronic plaque psoriasis - second line Tofacitinib for chronic plaque psoriasis – second line Tofacitinib for chronic plaque psoriasis – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Tofacitinib for chronic plaque psoriasis – second line . Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon (...) Scanning Review. 2015 Authors' objectives Tofacitinib is intended to be used as second line therapy for the treatment of chronic moderate-to-severe plaque psoriasis. If licensed, it will provide an additional oral treatment option for this patient group. Tofacitinib is a novel janus kinase (JAK) inhibitor that inhibits JAK1, 2 and 3 in vitro, with functional specificity for JAK1 and 3. Inhibition of JAK1 and 3 blocks signalling of several cytokines which are required for lymphocyte activation

2015 Health Technology Assessment (HTA) Database.

193. Tildrakizumab for moderate to severe plaque psoriasis

Tildrakizumab for moderate to severe plaque psoriasis Tildrakizumab for moderate to severe plaque psoriasis Tildrakizumab for moderate to severe plaque psoriasis NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Tildrakizumab for moderate to severe plaque psoriasis. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon (...) Scanning Review. 2015 Authors' objectives Tildrakizumab is intended for use in patients with moderate to severe plaque psoriasis who have failed to respond to, have contraindications to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (psoralen ultraviolet light) therapy. If licensed, it will offer an additional treatment option for these patients who have not responded to topical or systemic therapies, and offer an alternative to other biological agents

2015 Health Technology Assessment (HTA) Database.

194. Ixekizumab for moderate to severe chronic plaque psoriasis

Ixekizumab for moderate to severe chronic plaque psoriasis Ixekizumab for moderate to severe chronic plaque psoriasis Ixekizumab for moderate to severe chronic plaque psoriasis NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Ixekizumab for moderate to severe chronic plaque psoriasis. Birmingham: NIHR Horizon Scanning Research&Intelligence (...) Centre. Horizon Scanning Review. 2015 Authors' objectives Ixekizumab is intended for the treatment of moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy. If licensed, ixekizumab will offer an additional treatment option for this patient group. Treatment with ixekizumab may result in some patients achieving near/full clearance of psoriasis symptoms. Ixekizumab is a humanised immunoglobulin G subclass 4 (IgG4) monoclonal antibody that neutralises interleukin

2015 Health Technology Assessment (HTA) Database.

195. Psoriasis

Psoriasis Psoriasis - NICE CKS Share Psoriasis: Summary Psoriasis is a systemic, immune-mediated, inflammatory skin disease which typically has a chronic relapsing-remitting course, and may have nail and joint (psoriatic arthritis) involvement. Chronic plaque psoriasis (including scalp psoriasis, flexural psoriasis, and facial psoriasis) is the most common form, affecting 80–90% of people with psoriasis. The second most common form is localized pustular psoriasis of the palms and soles. Other (...) forms of psoriasis include: Guttate psoriasis. Nail psoriasis. Erythrodermic and generalized pustular psoriasis (rare medical emergencies, may be life-threatening). Psoriasis is common, with about 1.3–2.2% of the UK population affected. Several factors are associated with the onset or exacerbation of psoriasis, including infection, drugs (including corticosteroid withdrawal), ultraviolet light exposure, trauma, hormonal changes, stress, smoking, and alcohol. Psoriasis may be associated with other

2018 NICE Clinical Knowledge Summaries

196. Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis (Abstract)

Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis To evaluate the effect of brodalumab on psoriasis signs and symptoms assessed by the Psoriasis Symptom Inventory (PSI) in patients with psoriatic arthritis (PsA).This prespecified analysis of a phase II study (NCT01516957) evaluated patients with active PsA and psoriasis-affected body surface area ≥ 3%, randomized to brodalumab (140 or 280 mg (...) ) or placebo every 2 weeks (Q2W) for 12 weeks with loading dose at Week 1. At Week 12, patients entering an open-label extension received brodalumab 280 mg Q2W. The PSI measures 8 psoriasis signs and symptoms: itch, redness, scaling, burning, stinging, cracking, flaking, and pain. PSI response is defined as total PSI ≤ 8 (range 0-32), each item ≤ 1 (range 0-4). PSI scores were assessed at weeks 12 and 24.There were 107 eligible patients. At Week 12, mean improvement in PSI scores was 7.8, 11.2, and 1.5

2016 EvidenceUpdates Controlled trial quality: uncertain

197. Psoriasis: a personal view and a look at what works

Psoriasis: a personal view and a look at what works Psoriasis: a personal view and a look at what works - Evidently Cochrane Search and hit Go By June 17, 2016 // In this blog, Freya shares her story of living with psoriasis and Cochrane UK’s Senior Fellow in General Practice, Lynda Ware, looks at a recent Cochrane evidence on topical treatments for scalp psoriasis. Freya’s story “I first noticed that I had some kind of skin condition in my first year of university. Like most students I had (...) began to crop up over my whole body” It must have been a couple of months later that I noticed small patches of dry skin on my arms, little circles of redness, which began to crop up over my whole body. I went back to the doctors, this time to be told I had Guttate Psoriasis and it most likely appeared due to the previous illness being a streptococcal throat infection untreated by antibiotics. I was sent to get some sun, moisturise and was given an unpleasant greasy ointment to use on the patches

2016 Evidently Cochrane

198. Hypertension and risk of psoriasis incidence: An 11-year nationwide population-based cohort study. Full Text available with Trip Pro

Hypertension and risk of psoriasis incidence: An 11-year nationwide population-based cohort study. Psoriasis is a chronic inflammatory skin disease that is characterized by T-cell mediated immune response, and has been known to increase the risk of developing hypertension. However, the risk of psoriasis in patients with hypertension is not clear. Therefore, we investigated the risk of psoriasis in patients with hypertension. A total of 256,356 adults (42,726 in the hypertension group (...) and 213,630 in the control group) were followed from 2003 to 2013 in a nationwide population-based cohort study. During the follow-up, 9,254 participants (3.6%) were found to have psoriasis (2,152 [5.0%] in the hypertension group and 7,102 [3.3%] in the control group). The hypertension group had a higher risk of psoriasis incidence (hazard ratio [HR] 1.54, 95% confidence interval [CI] 1.47-1.61, P < 0.001), and the association remained significant after adjusting for comorbidities of diabetes

2018 PLoS ONE

199. The prevalence of cardiovascular diseases risk factors associated with psoriasis in Saudi Arabia Full Text available with Trip Pro

The prevalence of cardiovascular diseases risk factors associated with psoriasis in Saudi Arabia Extensive studies have revealed an increased risk of major adverse cardiac outcomes in patients with severe psoriasis. However, some studies show conflicting results.This study was conducted to assess the CV risk factors in psoriasis patients, and compare it with non-psoriatic patients. In addition, we evaluated if psoriasis is an independent CV risk factor, if its severity can predict CV risk (...) , and if systemic psoriasis treatments modify CV risk.This was a case-control study in 200 participants -100 with psoriasis, and 100 with dermatitis who served as the control. The study was carried out from September 2015 to September 2016. Data was collected using self-administered questionnaires, one each for both groups. Questions include body surface area, current psoriasis/dermatitis therapies, presence of diabetes mellitus, hypertension, smoking history, weight, height, body mass index (BMI), elevated

2017 Electronic physician

200. Role of mesenchymal stem cells in the pathogenesis of psoriasis: current perspectives Full Text available with Trip Pro

Role of mesenchymal stem cells in the pathogenesis of psoriasis: current perspectives Mesenchymal stem cells (MSCs) are multipotent nonhematopoietic stromal cells studied for their properties and importance in management of several skin diseases. This review collects and analyzes the emerging published data, which describe the function of MSCs in the pathogenesis of psoriasis.

2017 Psoriasis (Auckland, N.Z.)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>